查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
充血性心臟衰竭藥物市場，按類型、藥物類別、分銷管道、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測
市場調查報告書
商品編碼
1351452

充血性心臟衰竭藥物市場，按類型、藥物類別、分銷管道、國家和地區 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Congestive Heart Failure Drugs Market, By Type, By Drug Class, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 297 Pages | 商品交期: 2-3個工作天內

價格

報告要點

充血性心臟衰竭藥物 2022 年市場規模為 66.009 億美元，2023 年至 2030 年年複合成長率為 15.8%。

充血性心臟衰竭藥物市場-市場動態：

  • 老年人口的增加以及高血壓、肥胖和糖尿病發病率的增加預計將促進行業成長。
  • 老年人有更多的合併症，並且經常服用多種藥物，使他們更容易受到藥物交互作用和加劇心臟衰竭的影響。肥胖也與其他健康問題有關，例如睡眠呼吸中止症和糖尿病，這兩者都會增加心臟衰竭的風險。根據世界衛生組織的數據，2020 年有3,900 萬5 歲以下兒童超重或肥胖。隨著新興經濟體醫療保健基礎設施的發展，對現代醫療治療的需求日益成長，特別是治療慢性心臟衰竭等疾病的藥物，提供了成長機會為市場。然而，先進的治療方法，如心臟再同步治療 (CRT) 和其他醫療設備有時可以減少對藥物的需求。

充血性心臟衰竭藥物市場 - 主要見解：

  • 根據我們的研究分析師分享的分析，全球充血性心臟衰竭藥物市場預計在預測期內（2023-2030）每年將以 15.8% 左右的年複合成長率成長
  • 由於人們對永續成長的認知不斷增強，充血性心臟衰竭藥物產業預計將以顯著的速度成長
  • 根據類型細分，預計左心衰竭將在 2022 年呈現最大市場佔有率
  • 根據藥物類別細分，血管張力素 II 受體阻斷劑（ARB）是 2022 年的主導類型
  • 從分銷通路細分來看，2022年醫院藥局是主導類型
  • 按地區分類，北美是 2022 年的主要收入來源

充血性心臟衰竭藥物市場-細分分析：

  • 全球充血性心臟衰竭藥物市場根據類型、藥物類別、分銷管道和地區進行細分。
  • 市場依類型分為三類：左側心臟衰竭、右側心臟衰竭和高輸出量心臟衰竭。左側心臟衰竭較常見，又進一步細分為射血分數降低型心臟衰竭（HFrEF）和射血分數維持型心臟衰竭（HFpEF）。
  • 依藥物類別，市場分為兩類：ACE抑制劑、血管張力素2受體阻斷劑、BETA受體阻斷劑、利尿劑、醛固酮拮抗劑、正性肌力藥物等。血管張力素 2 受體阻斷劑在市場上佔據主導地位，並可能在預測期內保持其主導地位。血管張力素 II 受體阻斷劑 (ARB) 是一類重要的藥物，用於治療各種心血管疾病，包括充血性心臟衰竭 (CHF)，特別是無法耐受 ACE 抑制劑的患者。
  • 根據分銷管道，市場分為兩類：醫院藥房、零售藥房和線上藥房。醫院藥房產業佔據市場主導地位。醫院藥局對於各種疾病（包括充血性心臟衰竭（CHF））的藥物分配和配藥至關重要。

充血性心臟衰竭藥物市場-地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太、中東和非洲等地區。這些區域根據開展業務的國家進一步分類。由於醫療支出激增、對心臟健康的高度認知以及醫療保健服務可用性的增加，預計北美將推動充血性心臟衰竭藥物市場的成長。美國是世界上人均醫療費用最高的國家之一。這筆巨額支出不可避免地增加了獲得藥物和治療的機會。根據醫療保險和醫療補助服務中心的數據，2021 年美國醫療保健支出將增加 2.7%，達到 4.3 兆美元，即人均 12,914 美元。醫療支出佔國內生產毛額的比重為18.3%。由於研發活動支出的增加，歐洲成為該市場成長的第二大地區。

充血性心臟衰竭藥物市場-競爭格局：

充血性心臟衰竭 (CHF) 藥物市場有各種各樣的參與者，從老牌製藥巨頭到專注於尖端療法的新進者。雖然幾家著名的製藥公司正在開發治療慢性心臟衰竭的新療法，但學名藥也有很大的市場，特別是因為許多早期的慢性心臟衰竭治療方法的專利已經到期。 CHF 藥品市場已經發生了大量的併購，較大的企業收購較小的公司或與較小的公司合作，將新的治療方法引入其產品線。例如，2023年3月6日，默沙東（在美國和加拿大以外地區稱為MSD）宣布，美國食品藥物管理局（FDA）已批准可溶性鳥苷酸環化酶（sGC）刺激劑VERQUVO，用於降低心血管疾病風險有症狀的慢性心臟衰竭且射血分數低於 45% 的成人因心臟衰竭住院或需要門診靜脈注射 (IV) 利尿劑後死亡和心臟衰竭住院。

最近的發展：

2023 年3 月1 日，安進公司（NASDAQ：AMGN）宣布新的Repatha (evolocumab) 結合了3 期FOURIER 和FOURIER 開放標籤擴展(OLE) 研究以及在研olpasiran 的2 期OCEAN( a)-DOSE 研究資料。siRNA 可將脂蛋白 (a) [Lp(a)] 降低 90% 以上。

目錄

第一章：充血性心臟衰竭藥物市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按類型分類的充血性心臟衰竭藥物市場片段
    • 按藥物類別分類的充血性心臟衰竭藥物市場片段
    • 按分銷管道分類的充血性心臟衰竭藥物市場片段
    • 按國家/地區分類的充血性心臟衰竭藥物市場片段
    • 按地區分類的充血性心臟衰竭藥物市場片段
  • 競爭洞察

第 3 章：充血性心臟衰竭藥物主要市場趨勢

  • 充血性心臟衰竭藥物市場促進因素
    • 市場促進因素的影響分析
  • 充血性心臟衰竭藥物市場限制
    • 市場限制影響分析
  • 充血性心臟衰竭藥物市場機會
  • 充血性心臟衰竭藥物市場未來趨勢

第 4 章：充血性心臟衰竭藥物產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：充血性心臟衰竭藥物市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長部分
    • 最鬆散的部分
    • 邊際損失部分

第 6 章：充血性心臟衰竭藥物市場格局

  • 2022 年充血性心臟衰竭藥物市場佔有率分析
  • 按主要製造商分類的故障數據
    • 既定玩家分析
    • 新興玩家分析

第 7 章：充血性心臟衰竭藥物市場 - 按類型

  • 概述
    • 按類型分類的細分市場佔有率分析
    • 左心衰竭
    • 右心衰竭
    • 高輸出量心臟衰竭

第 8 章：充血性心臟衰竭藥物市場 - 按藥物類別

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • ACE抑制劑
    • 血管張力素 2 受體阻斷劑
    • BETA受體阻斷劑
    • 利尿劑
    • 醛固酮拮抗劑
    • 正性肌力藥
    • 其他

第 9 章：充血性心臟衰竭藥物市場 - 按分銷管道

  • 概述
    • 按分銷管道分類的細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第 10 章：充血性心臟衰竭藥物市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 充血性心臟衰竭藥物北美主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按類型）
    • 北美市場規模和預測（按藥物類別）
    • 北美市場規模和預測（按分銷管道）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲充血性心臟衰竭藥物主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模與預測（按類型）
    • 歐洲市場規模和預測（按藥物類別）
    • 歐洲市場規模和預測（按分銷管道）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區充血性心臟衰竭藥物主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（按類型）
    • 亞太地區市場規模和預測（按藥物類別）
    • 亞太地區市場規模和預測（按分銷管道）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲充血性心臟衰竭藥物主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按類型）
    • 拉丁美洲市場規模與預測（按藥物類別）
    • 拉丁美洲市場規模和預測（按分銷管道）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 充血性心臟衰竭藥物是中東和非洲的主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按類型）
    • 中東和非洲市場規模及預測（按藥物類別）
    • 中東和非洲市場規模及預測（按分銷管道）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 充血性心臟衰竭藥品產業

  • 競爭儀表板
  • 公司簡介
    • Bayer AG
    • Novartis AG
    • Merck & Co., Inc.
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Amgen Inc.
    • Boehringer Ingelheim International GmbH
    • Pfizer, Inc.
    • Johnson & Johnson Services, Inc.
    • Otsuka Pharmaceutical Co., Ltd.
    • Eli Lilly and Company
    • Novo Nordisk A/S

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV1694

REPORT HIGHLIGHT

Congestive heart failure drugs Market size was valued at USD 6,600.9 Million in 2022, expanding at a CAGR of 15.8% from 2023 to 2030.

Congestive heart failure (CHF) is a complex clinical illness caused by any anatomical or functional cardiac problem that inhibits the heart's ability to fill with or pump enough blood throughout the body. The most effective therapy for CHF is generally determined by the underlying cause of the heart failure, its severity, and any other medical disorders the patient may have. The goal of treatment for chronic congestive heart failure (CHF) is to enhance symptom management and quality of life, reduce hospitalizations, and lower overall mortality.

Congestive heart failure drugs Market - Market Dynamics:

  • A rise in the geriatric population and an increase in the incidence of hypertension, obesity, and diabetes are expected to augment industry growth.
  • Elderly people have more comorbid diseases and frequently take many drugs, making them more vulnerable to drug interactions and conditions that exacerbate heart failure. Obesity is also linked to other health issues such as sleep apnea and diabetes, both of which raise the risk of heart failure. According to the World Health Organization, 39 million children under the age of 5 were overweight or obese in 2020. As rising economies' healthcare infrastructure develops, there is an increasing need for modern medical treatments, especially medications for illnesses such as CHF providing growth opportunities for the market. However, Advanced treatments such as cardiac resynchronization therapy (CRT) and other medical devices can occasionally reduce the need for pharmaceuticals.

Congestive heart failure drugs Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Congestive heart failure drugs market is estimated to grow annually at a CAGR of around 15.8% over the forecast period (2023-2030)
  • The Congestive heart failure drugs industry is projected to grow at a significant rate due to the growing awareness of sustainable growth
  • Based on type segmentation, Left-sided Heart Failure was predicted to show maximum market share in the year 2022
  • Based on drug class segmentation, Angiotensin II Receptor Blockers (ARBs were the leading type in 2022
  • Based on distribution channel segmentation, hospital Pharmacies were the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Congestive Heart Failure Drugs Market- Segmentation Analysis:

  • The Global Congestive Heart Failure Drugs Market is segmented on the basis of Type, Drug Class, Distribution Channel, and Region.
  • The market is divided into three categories based on type: Left-sided Heart Failure, Right-sided Heart Failure, and High-output Heart Failure. Left-sided heart failure is more prevalent, and it is further subdivided into heart failures with reduced ejection fraction (HFrEF) and heart failures with maintained ejection fraction (HFpEF).
  • The market is divided into two categories based on Drug Class: ACE Inhibitors, Angiotensin 2 Receptor Blockers, Beta Blockers, Diuretics, Aldosterone Antagonists, Inotropes, and Others. The Angiotensin 2 Receptor Blockers dominate the market and are likely to maintain their dominance during the forecast period. Angiotensin II Receptor Blockers (ARBs) are an essential class of drugs used to treat a variety of cardiovascular disorders, including congestive heart failure (CHF), particularly in patients who cannot tolerate ACE inhibitors.
  • The market is divided into two categories based on Distribution Channels: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital Pharmacies sector dominates the market. Hospital pharmacies are essential in the distribution and dispensing of medications for a variety of diseases, including congestive heart failure (CHF).

Congestive heart failure drugs Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to drive the growth of the Congestive Heart Failure Drugs Market, due to a Surge in medical spending, high awareness about cardiac health, and an increase in the availability of healthcare services. The United States has one of the world's largest per capita healthcare expenses. This significant expenditure inevitably increases access to medications and therapies. According to the Center for Medicare and Medicaid Service, U.S. healthcare spending will grow 2.7 percent in 2021, reaching USD 4.3 trillion or USD 12,914 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 18.3 percent. Europe held the second largest region for the growth of this market, due to a rise in spending on research & development activities.

Congestive heart failure drugs Market- Competitive Landscape:

The market for congestive heart failure (CHF) medications has seen a variety of participants, ranging from established pharmaceutical behemoths to newer entrants focused on cutting-edge therapy. While several prominent pharmaceutical companies are developing novel treatments for CHF, there is also a substantial market for generic medications, especially because many of the earlier CHF treatments have had their patents expire. The CHF medicine market has seen a sufficient number of mergers and acquisitions, with larger players acquiring or collaborating with smaller companies to bring novel treatments into their pipelines. For Example, on 6 march 2023, Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%.

Recent Developments:

On March 1, 2023, Amgen (NASDAQ: AMGN) announced new Repatha (evolocumab) combined data from the Phase 3 FOURIER and FOURIER Open Label Extension (OLE) studies and the Phase 2 OCEAN(a)-DOSE study of investigational olpasiran, a siRNA that reduces lipoprotein(a) [Lp(a)] by more than 90%.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET KEY PLAYERS

  • Bayer AG
  • Novartis AG
  • Merck & Co., Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH
  • Pfizer, Inc.
  • Johnson & Johnson Services, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Novo Nordisk A/S

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY TYPE

  • Left-sided Heart Failure
  • Right-sided Heart Failure
  • High-output Heart Failure

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY DRUG CLASS

  • ACE Inhibitors
  • Angiotensin 2 Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Aldosterone Antagonists
  • Inotropes
  • Others

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CONGESTIVE HEART FAILURE DRUGS MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Congestive Heart Failure Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Congestive Heart Failure Drugs Market Snippet by Type
    • 2.1.2. Congestive Heart Failure Drugs Market Snippet by Drug Class
    • 2.1.3. Congestive Heart Failure Drugs Market Snippet by Distribution Channel
    • 2.1.4. Congestive Heart Failure Drugs Market Snippet by Country
    • 2.1.5. Congestive Heart Failure Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Congestive Heart Failure Drugs Key Market Trends

  • 3.1. Congestive Heart Failure Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Congestive Heart Failure Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Congestive Heart Failure Drugs Market Opportunities
  • 3.4. Congestive Heart Failure Drugs Market Future Trends

4. Congestive Heart Failure Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Congestive Heart Failure Drugs Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Congestive Heart Failure Drugs Market Landscape

  • 6.1. Congestive Heart Failure Drugs Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Congestive Heart Failure Drugs Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2022 & 2030 (%)
    • 7.1.2. Left-sided Heart Failure
    • 7.1.3. Right-sided Heart Failure
    • 7.1.4. High-output Heart Failure

8. Congestive Heart Failure Drugs Market - By Drug Class

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Class, 2022 & 2030 (%)
    • 8.1.2. ACE Inhibitors
    • 8.1.3. Angiotensin 2 Receptor Blockers
    • 8.1.4. Beta Blockers
    • 8.1.5. Diuretics
    • 8.1.6. Aldosterone Antagonists
    • 8.1.7. Inotropes
    • 8.1.8. Others

9. Congestive Heart Failure Drugs Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Congestive Heart Failure Drugs Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Congestive Heart Failure Drugs Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Congestive Heart Failure Drugs Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Congestive Heart Failure Drugs Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Congestive Heart Failure Drugs Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Congestive Heart Failure Drugs Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Congestive Heart Failure Drugs Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Bayer AG
    • 11.2.2. Novartis AG
    • 11.2.3. Merck & Co., Inc.
    • 11.2.4. AstraZeneca
    • 11.2.5. Bristol-Myers Squibb Company
    • 11.2.6. Amgen Inc.
    • 11.2.7. Boehringer Ingelheim International GmbH
    • 11.2.8. Pfizer, Inc.
    • 11.2.9. Johnson & Johnson Services, Inc.
    • 11.2.10. Otsuka Pharmaceutical Co., Ltd.
    • 11.2.11. Eli Lilly and Company
    • 11.2.12. Novo Nordisk A/S

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Congestive Heart Failure Drugs Market: Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Type
  • TABLE Global Congestive Heart Failure Drugs Market, by Type 2018-2030 (USD Million)
  • TABLE Congestive Heart Failure Drugs Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Congestive Heart Failure Drugs Market, by Drug Class 2018-2030 (USD Million)
  • TABLE Congestive Heart Failure Drugs Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Congestive Heart Failure Drugs Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Congestive Heart Failure Drugs Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Congestive Heart Failure Drugs Market, by Region 2018-2030 (USD Million)
  • TABLE North America Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE North America Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE Europe Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE Latin America Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Congestive Heart Failure Drugs Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Congestive Heart Failure Drugs Market, by Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Congestive Heart Failure Drugs Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Congestive Heart Failure Drugs Market, by Distribution Channel, 2018-2030 (USD Million)

List of Figures

  • FIGURE Congestive Heart Failure Drugs Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Type segment market share analysis, 2022 & 2030
  • FIGURE Type segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Drug Class segment market share analysis, 2022 & 2030
  • FIGURE Drug Class segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Distribution Channel segment market share analysis, 2022 & 2030
  • FIGURE Distribution Channel segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Congestive Heart Failure Drugs Market share and leading players, 2022
  • FIGURE Europe Congestive Heart Failure Drugs Market share and leading players, 2022
  • FIGURE Asia Pacific Congestive Heart Failure Drugs Market share and leading players, 2022
  • FIGURE Latin America Congestive Heart Failure Drugs Market share and leading players, 2022
  • FIGURE Middle East and Africa Congestive Heart Failure Drugs Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Congestive Heart Failure Drugs Market share analysis by country, 2022
  • FIGURE Germany Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Congestive Heart Failure Drugs Market share analysis by country, 2022
  • FIGURE India Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Congestive Heart Failure Drugs Market share analysis by country, 2022
  • FIGURE Brazil Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Congestive Heart Failure Drugs Market share analysis by country, 2022
  • FIGURE Saudi Arabia Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Congestive Heart Failure Drugs Market size, forecast and trend analysis, 2018 to 2030 (USD Million)